Member Info for researcher1

Good question! ask Newland, if you wouldn't mind? - I can't stand speaking to the bloke. There's no reason why revenues shouldn't be shooting up, if Angle were led by anyone with an ounce of acumen.

If you don't know the answer to your own question TG2D then you should sell up. Angle is obviously high risk (especially with Newland at the helm) but the reason I've bought back in is that the Parsortix method of CTC capture is world-leading, actually because it is the simplest harvesting method, one which produces no contamination, is not prone to skewed results (like other systems) and is far cheaper than every other platform.

Yup, that's AN - a good day to buy in for the next empty ramp though :-)

Cleaner, when the data breaks through the quality of the website will not matter !

I wouldn't get your hopes up TF, if it was genuinely new data, there would be a responsibility to RNS it as soon as it was analysed (i.e. before they would have had a poster accepted).

Totally agree moon, a little more patience folks....

Can you elaborate a little more please roses?

Can anyone explain the derivative liability issue in relation to Scancell?

I was on holiday :-(

I've been wanting to buy in under 20p for ages, so thanks to the PR team for garbling what should be a super-positive RNS!

Spot on fevertree - don't touch with bargepole....

That's what AN wants you to do liam, imagine.

Another dreadful update with the usual vague obfuscations - AN should be ashamed of himself (not to mention his lapdog Griffiths)- the same old promises of the past 3 years, with no progress, except perhaps for the hiring of new people they can't afford. If you think the SP is cheap at the moment, just wait until it sinks to 8p.

3 world-leading cancer platforms for 9.7p a share - keep buying, I say....

Children, pack it in please. I hope everyone bought as much as they could around 9.3p?

Time to buy, Iofas?

Anyone else think that the US will take this announcement more seriously (tomorrow), especially with the patent news to digest??

Bojo, I understand your wish for a larger sample, but personally I find the numbers compelling, and more than likely to be replicated in larger studies - perhaps even exceeded. These are tough cancers to influence and that Modi has had such an impact I find extraordinary.

Absolutely Rob - the market has lost a zero from the MCAP - and that's just for starters!

Thanks - I agree it may not be Calculus selling, and that it doesn't make much difference really - once results begin to stack up, everyone will want a piece of SCLP action! Happy 2025 to all....